Buyback Announcements and News

4/21/2025

Follow-up: Medpace board approves $1.0B increase to company's stock repurchase program - 8-K ($288.99, 0.00)

  • During Q1 of 2025, the company repurchased 1.2M shares at an average price of $326.78 per share for a total of $389.8M.
    • As of 31-Mar-25, the company had $344.8M remaining under its authorized share repurchase program.
  • Additionally, on 17-Apr-25, the company's board approved an increase of $1.0B to the company's stock repurchase program.

4/21/2025

Calix, Inc increases stock repurchase authorization by additional $100M ($33.25, 0.00)

4/21/2025

StreetAccount Summary - Notable US Dividend & Share Repurchase Announcements: Week of 14-Apr

  • Dividends: StreetAccount has tracked 10 dividend increases during the week of 14-Apr through 20-Apr.
    • Dividend Increases/Initiations:
      • Basic Materials
        • 15-Apr: H.B. Fuller increases quarterly dividend by 5.6% to $0.235 from $0.2225 (FUL)
        • 16-Apr: Sonoco Products increases quarterly dividend by 1.9% to $0.53 from $0.52 (SON)
      • Energy
        • 17-Apr: Star Group increases quarterly distribution by 7.2% to $0.185 from $0.1725 (SGU)
      • Financial
        • 15-Apr: Interactive Brokers Group increases quarterly dividend by 28.0% to $0.32 from $0.25 (IBKR)
        • 16-Apr: Travelers Cos. increases quarterly dividend by 4.8% to $1.10 from $1.05 (TRV)
        • 17-Apr: Bar Harbor Bankshares increases quarterly dividend to $0.32/sh (BHB)
      • Healthcare
        • 15-Apr: Johnson & Johnson increases quarterly dividend by 4.8% to $1.30 from $1.24 (JNJ)
      • Services
        • 16-Apr: Winmark increases quarterly dividend by 6.7% to $0.96 from $0.90 (WINA)
        • 16-Apr: Costco Wholesale increases quarterly dividend by 12.1% to $1.30 from $1.16 (COST)
      • Utilities
        • 19-Apr: Portland General Electric increases quarterly dividend by 5.0% to $0.525 from $0.50 (POR)
  • Share Repurchases: StreetAccount has tracked 9 share repurchase increases/resumptions during the week of 14-Apr through 20-Apr.
    • New/Increased Repurchase Authorizations:
      • Capital Goods
        • 17-Apr: D.R. Horton announces new share repurchase authorization of $5.0B (DHI)
      • Consumer Non-Cyclical
        • 17-Apr: Better Choice Company reinstates stock repurchase program and increases authorization to $6.5M (BTTR)
      • Energy
        • 15-Apr: Montauk Renewables, Inc. authorized a share repurchase program to repurchase up to $5.0M of the company's outstanding common stock (MNTK)
      • Financial
        • 14-Apr: Goldman Sachs approved a share repurchase program authorizing repurchases of up to $40B of common stock (GS)
        • 16-Apr: Civista Bancshares board approve stock repurchase program of up to $13.5M (CIVB)
        • 17-Apr: Huntington Bancshares approves $1B share repurchase authorization (HBAN)
      • Healthcare
        • 14-Apr: Certara announces new $100M buyback and one year lock-up with holder Arsenal Capital (CERT)
        • 17-Apr: Atea Pharmaceuticals announces share repurchase program for up to $25M (AVIR)
        • 17-Apr: Pacira BioSciences authorized a share repurchase program of up to an aggregate of $300M (PCRX)

4/19/2025

One Stop Systems holder Horton Capital discloses its board member Joseph Manko has submitted his resignation letter to the board - 13D/A ($2.12, 0.00)

  • Manko, who has been serving as a director of the company since November 2023, submitted a letter of resignation to the company's board resigning from the board, effective 16-Apr-25.
  • In the Resignation Letter, Manko cited certain disagreements with the company's governance practices and the composition and leadership of the board, particularly with respect to Chairman Kenneth Potashner.
  • More specifically, Potashner was nominated by the board for re-election at the company's 2025 annual meeting, a decision that Manko objected to in his capacity as a director, despite the company's shareholders voting against the Chairman's re-election two years in a row.
  • The board's decision to renominate the Chairman for election at the 2025 Annual Meeting, in Manko's opinion, represents a failure of the board to represent the best interest of all shareholders.
  • For this reason, as well as others discussed in further detail in the Resignation Letter, Manko resigned from the board, a decision that he did not take lightly.
  • Given Manko's conviction in the value potential of the company, he disclosed in the Resignation Letter that he intends to remain a shareholder of the company and reserves all rights to take any action that he deems necessary to represent the best interests of all of shareholders. A copy of the Resignation Letter is linked below
  • Horton Capital owns a 5.5% stake

4/19/2025

Insider transaction: Zymeworks holder Ecor1 Capital discloses purchases of additional 128.7K shares - Form 4 ($11.53, 0.00)

  • Ecor1 Capital beneficially owns 17.8M shares of common stock following the transactions

4/19/2025

Vacasa Special Committee finds Davidson Kempner's revised proposal unlikely to be superior to that from Vacasa ($5.42, 0.00)

  • The Special Committee determined that the Proposal was not reasonably likely to be consummated in accordance with its terms, so long as the Proposal remained conditioned upon receipt of an amendment to the company's Tax Receivable Agreement and subject to materially greater risks regarding closing certainty than the Casago transaction. The Special Committee takes its fiduciary duties to act in the best interests of public stockholders extremely seriously and strongly disagrees with the various assertions made by Davidson Kempner in its most recent proposal letters. Notwithstanding Davidson Kempner's proposed purchase price of $5.83 per share, the Special Committee cannot support a transaction that is not actionable and has significantly less certainty of closing than the transaction with Casago, especially in light of recent market volatility and uncertainty.

4/17/2025

Pacira BioSciences announces share repurchase program ($24.65, 0.00)

  • The board has authorized a share repurchase program of up to an aggregate of $300M with respect to the company's common stock, under the same terms as the authorization announced on 7-May-24 and replacing the prior authorization
  • The share repurchase authorization expires at the end of December 2026
  • The board and management team stated long term objectives, planning to achieving the following key objectives by 2030:
    • Treating more than 3M patients per year
    • Achieving a double-digit compounded annual growth rate for revenue
    • Improving gross margins by 5 percentage points over 2024
    • Expanding the company's clinical pipeline with 5 novel programs in development
    • Establishing 5 new partnerships including pipeline and commercial agreements

4/17/2025

Insider transaction: Calavo Growers CEO Lecil Cole discloses purchase of ~38.2K shares - Form 4 ($25.25, +0.59)

  • Cole beneficially owns ~574.2K shares of common stock following the transaction.

4/17/2025

Better Choice Company reinstates stock repurchase program and increases authorization to $6.5M ($1.87, 0.00)

  • Better Choice Company, Inc.'s board has reinstated its stock repurchase program and increased authorization up to $6.5M of its outstanding shares of common stock, until 31-Dec-25.
  • The company repurchased 102,405 common shares at an average price of $1.9869 per share under the previous $5M stock repurchase program, which expired on 31-Dec-24.

4/17/2025

Cass Information Systems reports Q1 EPS $0.66 vs FactSet $0.60 [1 est] ($39.68, 0.00)

  • Reports Q1:
    • Revenue $46.4M vs FactSet $51.5M [1 est]
    • Net interest margin 3.75%
    • Repurchased 116,109 shares of Company stock at weighted average price of $42.86.
  • Management Comments:
    • "Our quality financial results for Q1 show progress toward our strategic plan and I am proud of the team's execution. The positive results reflect our ongoing successful implementation of efficiency initiatives powered by technology, combined with an increase in our revenue driven by net interest income. The combination of continued efficiencies via technology, improvement in our net interest margin and the closure of pipeline opportunities in our Transportation and Facility lines of business should result in meaningful profitability improvement over recent quarters. In addition, the successful sale of our TEM business will enable us to concentrate on our strengths in financial exchange and information processing."